Civil Law and Clinical Research Contract Claims in Europe

1. Introduction

Clinical research contract claims arise when parties involved in medical or pharmaceutical research dispute their contractual rights and obligations.

Typical parties include:

pharmaceutical sponsor;

biotechnology company;

Contract Research Organisation (CRO);

hospital;

university;

principal investigator;

research foundation;

research site;

laboratory;

data-management provider;

patient/participant in situations where contractual and civil-liability issues overlap.

A Clinical Trial Agreement (CTA) normally regulates matters such as:

performance of the clinical trial;

protocol compliance;

recruitment and screening;

personnel and facilities;

payment and research costs;

ownership and use of research data;

intellectual property;

confidentiality;

publication;

monitoring and auditing;

insurance;

indemnification;

termination;

regulatory compliance;

dispute resolution.

EU Regulation 536/2014 is particularly important. It permits sponsors to delegate tasks by written contract, but expressly provides that delegation does not remove the sponsor's responsibility, particularly for participant safety and data reliability. It also addresses co-sponsors, principal investigators, liability and damage-compensation systems. (EUR-Lex)

2. Meaning of Clinical Research Contract Claims

A clinical research contract claim can involve either performance of the research or commercial consequences of the research.

Examples

A sponsor may claim:

“The CRO failed to conduct the trial according to the agreed protocol.”

A CRO may claim:

“The sponsor failed to pay agreed research fees.”

A hospital may claim:

“The sponsor cannot require the hospital to undertake activities outside the CTA.”

A sponsor may claim:

“The CRO improperly withheld clinical-trial data.”

An investigator may claim:

“The institution cannot terminate the research arrangement without complying with the contractual termination mechanism.”

Therefore, clinical research disputes combine ordinary contract law with special medical-research regulation.

3. European Legal Framework

The principal EU instrument is Regulation (EU) No. 536/2014 on clinical trials on medicinal products for human use.

The Regulation defines:

sponsor as the person or organisation responsible for initiation, management and financing;

investigator as the person responsible for conducting the trial at the clinical-trial site. (EUR-Lex)

Article 71

A sponsor may delegate some or all tasks through a written contract.

But:

Delegation does not automatically transfer the sponsor's ultimate regulatory responsibility.

(EUR-Lex)

Article 72

Where several sponsors exist, their responsibilities may be divided through a written contract. If the contract fails to allocate a particular responsibility, the Regulation can leave responsibility with all sponsors. (EUR-Lex)

Article 73

The principal investigator must ensure compliance with the Regulation at the trial site. (EUR-Lex)

Article 75

The Regulation expressly preserves the civil and criminal liability of:

sponsors;

investigators;

persons to whom sponsor tasks have been delegated. (EUR-Lex)

Article 76

Member States must maintain systems for compensating subjects for damage resulting from participation in clinical trials, through insurance, guarantees or equivalent arrangements appropriate to the nature and extent of the risk. (EUR-Lex)

4. Contractual Allocation of Responsibility

A well-drafted CTA should distinguish at least four levels of responsibility.

A. Sponsor

Usually responsible for:

trial design;

financing;

regulatory submissions;

safety systems;

overall trial management;

pharmacovigilance;

data integrity.

B. CRO

Usually responsible for delegated activities such as:

site management;

monitoring;

recruitment support;

data management;

trial logistics;

clinical operations.

C. Hospital/site

Usually responsible for:

facilities;

staff;

local implementation;

institutional approvals;

investigator support.

D. Principal investigator

Usually responsible for:

medical conduct of the trial;

protocol compliance;

participant safety;

accurate clinical documentation.

The contractual allocation cannot necessarily override mandatory statutory responsibilities.

5. Main Types of Clinical Research Contract Claims

5.1 Non-performance

Example:

A CRO agrees to recruit 100 participants but does not undertake the agreed recruitment programme.

Possible remedies:

specific performance;

damages;

termination;

replacement of the CRO;

contractual penalties where valid.

5.2 Delay

Clinical research is extremely time-sensitive.

Delay may affect:

regulatory milestones;

financing;

patent strategy;

investor commitments;

trial completion;

market-entry plans.

A CTA may therefore contain detailed milestone provisions.

5.3 Failure to provide facilities

A hospital or CRO may promise:

clinical rooms;

laboratories;

pharmacy;

equipment;

qualified personnel.

Failure to maintain these resources can constitute contractual breach.

5.4 Failure to recruit participants

Recruitment obligations frequently generate disputes.

However, the court must distinguish between:

best-efforts obligation

and

guaranteed numerical result.

A party should not automatically be treated as having breached merely because the target number of participants was not achieved.

The contractual language is crucial.

6. Data Ownership and Clinical Trial Data

Clinical research generates enormous quantities of:

patient data;

laboratory results;

imaging;

electronic case report forms;

statistical information;

source documents;

trial databases.

A CTA should specify:

who owns physical records;

who controls the database;

who may access data;

who may use data;

who may publish results;

who may transfer data;

what happens after termination.

This issue became particularly significant in DiaMedica v PRA.

The Amsterdam court held that, under Dutch property law, digital clinical-trial data could not simply be treated as property capable of ownership in the same way as physical objects. The contractual relationship was governed by New York law, while the property-law question concerning data situated in the Netherlands was governed by Dutch law.

This illustrates an important principle:

Contractual control over data is not necessarily identical to proprietary ownership of data.

7. Publication Rights

Clinical research contracts often contain disputes over:

publication of results;

sponsor review;

confidentiality;

academic freedom;

adverse findings;

negative trial results.

Dutch clinical-research guidance specifically recognises CTA provisions concerning premature termination and publication of research results as matters subject to contractual review. (ccmo.nl)

A contract that gives the sponsor unlimited power to suppress publication may therefore encounter regulatory, ethical or contractual difficulties.

8. Intellectual Property

Clinical research can generate:

inventions;

pharmaceutical formulations;

diagnostic methods;

research techniques;

software;

databases;

biomarkers;

improvements to existing technology.

The CTA should determine:

background IP;

foreground IP;

ownership;

licences;

patent filing;

employee/investigator inventions;

publication rights;

post-termination rights.

9. Payment Disputes

A CTA may contain:

start-up fees;

per-patient payments;

milestone payments;

pass-through expenses;

monitoring fees;

laboratory costs;

administrative charges;

termination payments.

A common dispute is:

Whether the sponsor must pay where the trial has been stopped before all milestones are achieved.

The answer depends upon the contractual allocation of risk.

10. Termination of Clinical Research Contracts

Termination may occur because of:

regulatory action;

safety concerns;

insufficient recruitment;

commercial reasons;

loss of funding;

CRO failure;

hospital closure;

investigator departure;

protocol problems.

The key legal questions are:

Was termination permitted?

Was notice required?

Was there a contractual cure period?

Was immediate termination permitted for safety?

Who bears wind-down costs?

Who retains data?

Who informs participants?

What happens to investigational products?

11. Case Law

Case 1 — DiaMedica Therapeutics Inc. v PRA

Netherlands Commercial Court, ECLI:NL:RBAMS:2024:732, 7 February 2024

This is one of the most directly relevant European cases for clinical research contract litigation.

Facts

DiaMedica, a pharmaceutical company, entered into a clinical-trial management agreement with PRA, a CRO.

The trial concerned DiaMedica's drug DM-199.

DiaMedica alleged that PRA:

made misleading statements concerning study design;

provided allegedly unreliable interim results;

failed to provide complete study data;

failed to provide appropriate access to the study site.

DiaMedica sought approximately US$74 million in damages. (Rechtspraak)

Legal issues

The court considered:

contractual interpretation;

governing law;

alleged pre-contractual representations;

access to clinical data;

causation;

damages.

The agreement contained a New York law clause.

Decision

The court rejected the principal claims.

Among other things, DiaMedica had not established the necessary causal connection between the alleged conduct and the claimed loss. (Rechtspraak)

Importance

This case demonstrates:

A clinical-research contract claim still requires proof of breach, legally relevant loss and causation.

It also shows the importance of a carefully drafted governing-law clause.

Case 2 — DiaMedica Therapeutics Inc. v PRA

ECLI:NL:RBAMS:2023:2540, Netherlands Commercial Court, 21 April 2023

This was an earlier judgment in the same litigation.

Issue

DiaMedica sought control/recovery of documents and clinical-trial data.

Decision

The court distinguished between:

physical documents; and

digital clinical-trial data.

The court concluded that physical documents could constitute property, whereas digital data could not simply be treated as an owned corporeal object under the Dutch Civil Code.

Importance

This is highly significant for modern clinical research because trial contracts frequently use language such as:

“all study data shall be owned by the sponsor.”

The case demonstrates that contractual language concerning control and access should not automatically be confused with proprietary ownership under national property law.

Case 3 — Citryll B.V. v QPS Netherlands B.V.

ECLI:NL:RBDHA:2024:6634, District Court of The Hague, 10 April 2024

This is another highly direct CTA case.

Facts

Citryll and QPS entered into a CTA concerning a Phase I clinical trial of CIT-013.

QPS was responsible for supplying:

clinic facilities;

pharmacy;

personnel;

equipment;

recruitment;

screening;

other clinical-trial services.

QPS announced that it would close its Dutch operations.

Citryll argued that this threatened the continuation of the clinical trial. (InView)

Claim

Citryll sought enforcement of QPS's contractual obligations.

Decision

The court substantially ordered performance of the CTA obligations.

The case therefore illustrates the availability of specific performance/injunctive relief where a clinical research contract is at risk of being interrupted.

Importance

Clinical research is often highly time-sensitive.

Consequently, damages may not always provide an adequate remedy.

A court may therefore be asked to preserve:

the research site;

recruitment;

facilities;

staff;

trial continuity.

Case 4 — Citryll B.V. v QPS Netherlands B.V.

ECLI:NL:RBDHA:2024:8741, District Court of The Hague, 31 May 2024

This was a subsequent procedural stage of the Citryll-QPS dispute.

Issue

The dispute concerned the continued implementation and enforcement of obligations arising from the CTA after QPS's closure of its Groningen facilities.

QPS argued that it had arranged for another organisation, ICON, to undertake relevant activities. (Rechtspraak)

Importance

The litigation demonstrates a recurring clinical-research contractual problem:

Can a CRO discharge its obligations by subcontracting or transferring performance to another provider?

The answer depends on:

the CTA;

delegation clauses;

regulatory requirements;

approval requirements;

identity and qualifications of the replacement organisation;

sponsor consent.

This is particularly important because EU Regulation 536/2014 itself permits delegation by written contract but does not simply erase the sponsor's regulatory responsibility. (EUR-Lex)

Case 5 — Stichting Researchfonds Cardiologie v Canisius-Wilhelmina Ziekenhuis

ECLI:NL:RBGEL:2023:6908, District Court of Gelderland, 19 December 2023

Facts

A cardiology research foundation sought an order requiring a hospital to sign and implement a CTA concerning a clinical trial involving Milvexian.

The hospital's board had declined to approve the CTA.

The dispute involved:

institutional approval;

financial transparency;

governance of medical research;

the hospital's responsibility for research conducted within its institution. (Semantius)

Decision

The court held that the hospital's board had its own responsibility for evaluating clinical research agreements.

The internal approval process was not merely a formality.

The court did not find contractual or tortious liability merely because the hospital declined to approve the CTA in the circumstances.

Importance

This case establishes an important practical proposition:

A proposed CTA does not necessarily become enforceable merely because most of an internal approval procedure has been completed.

Institutional governance remains important.

Case 6 — Cardio Research Delft B.V. v Reinier de Graaf Groep

ECLI:NL:RBDHA:2026:19626, District Court of The Hague, 16 July 2026

Facts

Cardio Research Delft and cardiologists challenged the termination/change of their cooperation with a hospital concerning cardiological research.

The research involved sponsor-initiated and researcher-initiated studies.

Clinical research agreements were concluded among relevant parties, including sponsors, the hospital and principal investigators. (Rechtspraak)

The hospital had introduced a new policy concerning the financing and organisational structure of research.

Legal issue

Could the hospital terminate or reorganise the continuing cooperation?

Decision

The court held that the hospital was not required to continue the cooperation on the claimed basis. To the extent the relationship could be characterised as an indefinite-duration continuing contract, the hospital had sufficiently weighty grounds for termination in the circumstances.

Importance

This is particularly relevant to long-running clinical research relationships.

It demonstrates that litigation may concern not only individual CTA breaches but also:

termination;

institutional governance;

research financing;

continuing contractual relationships;

conflicts of interest;

restructuring of research operations.

Case 7 — Traskunova v Russia

ECtHR, Application No. 21648/11, judgment 30 August 2022

This is not a private CTA dispute, but it is an important European authority concerning the participant-protection side of clinical research.

Facts

A participant died while taking part in a clinical trial of a new medicinal product for schizophrenia.

The case concerned allegations that:

the regulatory framework had not been effectively implemented;

informed consent safeguards had not been adequately respected;

the participant's health had not been adequately monitored.

(Bailii)

Decision

The ECtHR found a violation of Article 2 of the Convention.

It emphasised the State's positive obligations concerning clinical trials and the need for particularly strong safeguards in circumstances involving vulnerable participants.

Importance

The case demonstrates that clinical research contracts cannot be viewed solely as commercial agreements.

They operate within a framework of:

human dignity;

informed consent;

participant safety;

regulatory supervision;

fundamental rights.

Nature of authority: human-rights/public-law authority rather than a private contractual damages case.

Case 8 — Verigraft v EISMEA

General Court, T-457/20, judgment 13 July 2022

This case concerns EU research funding and contractual grant obligations, rather than a conventional CTA.

Facts

Verigraft disputed the treatment of certain subcontracting costs connected with changes to clinical-trial sites.

The dispute involved:

clinical-trial sites;

subcontracting;

project amendments;

eligible expenditure;

EU grant obligations.

The General Court considered arguments concerning subcontracting costs arising from changes in clinical-trial sites from Norway to Lithuania and Spain. (EUR-Lex)

Importance

The case illustrates that clinical research disputes can extend beyond the CTA itself into:

EU grant agreements;

eligible costs;

subcontracting;

amendments;

funding compliance.

12. What These Cases Show

The European cases demonstrate several recurring principles.

13. Sponsor–CRO Contract Claims

A particularly important relationship is:

Sponsor ↔ CRO

The sponsor may allege:

failure to follow protocol;

recruitment failures;

poor monitoring;

inaccurate data;

regulatory non-compliance;

delay;

unauthorised subcontracting;

failure to deliver databases.

The CRO may respond:

the sponsor changed the protocol;

recruitment targets were unrealistic;

the sponsor failed to supply materials;

the sponsor failed to pay;

regulatory delays were outside the CRO's control;

the alleged loss was too remote.

The contract should therefore establish detailed responsibility matrices.

14. Hospital–Sponsor Claims

The relationship between:

Sponsor ↔ Hospital

can involve:

site access;

facilities;

investigator availability;

patient recruitment;

research fees;

regulatory approvals;

data access;

publication.

The Researchfonds v CWZ case shows why institutional approval should not be treated as a purely administrative signature. The hospital may have independent responsibilities concerning research conducted within its premises. (Semantius)

15. Investigator Liability

The investigator may have both:

Contractual duties

Under:

CTA;

investigator agreement;

employment agreement;

institutional agreement.

Regulatory/professional duties

Under:

clinical-trial regulation;

national medical law;

professional standards;

ethics requirements.

EU Regulation 536/2014 expressly preserves the investigator's civil and criminal liability under applicable law. (EUR-Lex)

16. CRO Delegation and Subcontracting

A CRO may want to subcontract:

laboratory testing;

monitoring;

data management;

recruitment;

pharmacovigilance;

site management.

The CTA should answer:

Can the CRO subcontract without sponsor approval?

If the contract requires prior consent, unauthorised subcontracting may constitute breach.

But regulatory responsibility cannot simply be contractually eliminated.

This follows from the structure of Regulation 536/2014: delegation is permitted, while sponsor responsibility concerning trial safety and data reliability remains protected. (EUR-Lex)

17. Data Claims

Clinical research data can create several distinct claims:

Access claim

“Give us the data.”

Confidentiality claim

“Do not disclose the data.”

Intellectual-property claim

“We own the database/invention.”

Privacy claim

“The proposed use violates data-protection law.”

Contractual-use claim

“You may use the data only for the purposes specified in the CTA.”

The DiaMedica litigation illustrates why these claims must not be collapsed into one concept of “ownership.”

18. Confidentiality

Clinical research contracts commonly protect:

investigational-product information;

trial protocols;

unpublished results;

commercial strategy;

patient-related information;

manufacturing information.

However, confidentiality clauses may have to coexist with:

mandatory regulatory disclosure;

clinical-trial transparency;

publication rights;

court orders;

participant rights.

A clause cannot necessarily prevent disclosure that the law requires.

19. Clinical Trial Delays

Delay can result from:

regulatory approval;

ethics review;

recruitment;

site readiness;

manufacturing;

laboratory testing;

safety issues;

database problems.

The legal question is not simply:

“Was the trial late?”

It is:

Who contractually assumed the risk of that particular delay?

A CTA should therefore contain:

milestones;

dependencies;

extension mechanisms;

force majeure provisions;

regulatory-delay clauses;

change-control procedures.

20. Force Majeure

Possible events include:

pandemics;

war;

regulatory shutdown;

natural disasters;

supply-chain failures;

cyberattacks.

A force-majeure clause may excuse performance if the specified conditions are satisfied.

But the party invoking force majeure generally needs to show that the event falls within the contractual clause and actually affected performance.

21. Clinical Trial Termination and Safety

A clinical trial can sometimes need to stop immediately because of:

serious adverse events;

unexpected safety signals;

regulatory intervention;

participant risk.

This creates a tension:

Commercial contract obligations

versus

participant safety obligations.

The latter cannot simply be subordinated to commercial performance.

Regulation 536/2014 specifically emphasises participant safety and provides mechanisms for modification, suspension and revocation of trials. (EUR-Lex)

22. Participant Injury Claims

A participant's injury may generate:

Contract-related issues

Depending on the applicable national law and contractual structure.

Tort/delict claims

Against:

investigator;

hospital;

sponsor;

CRO.

Statutory compensation

Under the applicable national clinical-trial compensation system.

Insurance claims

Against the relevant clinical-trial insurance arrangement.

EU Regulation 536/2014 deliberately leaves the substantive conditions of civil liability—including causation and damages—to national law. (EUR-Lex)

This is one of the most important points in European clinical-research litigation.

23. Causation

Suppose a participant suffers liver damage.

The claimant must potentially establish:

clinical trial participation → investigational product → medical injury → legally attributable damage.

Possible competing causes include:

underlying disease;

other medication;

unrelated medical condition;

pre-existing injury.

Different Member States may apply different approaches to:

burden of proof;

presumptions;

expert evidence;

causation;

contributory negligence.

Therefore, there is no single EU-wide private-law test for clinical-trial causation.

24. Insurance and Indemnification

A CTA should clearly distinguish:

Sponsor indemnity

Protection given by sponsor for specified claims.

CRO indemnity

Protection for specified CRO failures.

Institutional indemnity

Protection concerning institutional activities.

Clinical-trial insurance

Compensation system for participant harm.

These mechanisms should not be treated as identical.

Article 76 of Regulation 536/2014 requires Member States to maintain appropriate damage-compensation systems for clinical-trial participants. (EUR-Lex)

25. Governing Law

International clinical trials frequently involve:

US sponsor + Dutch CRO + German hospital + French participants + Italian laboratory.

A single CTA might contain a governing-law clause selecting one national law.

But mandatory rules of the country where the trial takes place may still apply.

This is particularly important because Regulation 536/2014 deliberately leaves civil liability, causation and damages to national law. (EUR-Lex)

26. Jurisdiction

A CTA should specify:

competent courts;

arbitration;

seat;

governing law;

interim-relief jurisdiction.

Clinical research creates an especially strong need for interim remedies.

For example:

“Do not close the clinical facility.”

or:

“Release the clinical-trial database.”

The Citryll litigation illustrates how urgent court proceedings can be used to address threatened interruption of clinical research. (InView)

27. Civil-Law Remedies

Depending on national law, courts may grant:

1. Specific performance

Ordering a party to perform CTA obligations.

2. Injunction

Preventing conduct that would disrupt research.

3. Damages

Compensation for proven contractual loss.

4. Termination

Ending the CTA following serious breach.

5. Declaratory relief

Determining contractual rights.

6. Data delivery/access

Ordering contractual information or records to be provided.

7. Restitution

Returning money or property following termination.

28. Important Civil-Law Principle: Contract vs Regulatory Duty

A critical distinction is:

A regulatory obligation does not automatically become a contractual obligation between private parties.

Conversely:

A contractual promise does not necessarily remove an independent statutory obligation.

For example, if a sponsor delegates monitoring to a CRO, the CTA may allocate operational responsibility to the CRO, but Regulation 536/2014 prevents contractual delegation from simply eliminating the sponsor's regulatory responsibility. (EUR-Lex)

29. Clinical Research and Good Faith

Civil-law systems commonly use good-faith principles to regulate contractual performance.

Good faith may become relevant to:

cooperation;

disclosure;

interpretation;

termination;

exercise of contractual discretion;

renegotiation;

prevention of opportunistic conduct.

But good faith does not automatically rewrite the CTA.

The court must balance:

contractual certainty

against

mandatory law and good-faith performance.

30. Key Future Litigation Areas

Clinical research contract litigation in Europe is likely to increasingly concern:

AI-generated clinical-trial data;

AI monitoring of trial participants;

decentralized clinical trials;

remote patient monitoring;

electronic consent;

wearable-device data;

cross-border data transfers;

cloud-based trial databases;

CRO subcontracting;

research-data ownership;

publication suppression;

protocol deviations;

clinical-trial insurance;

participant compensation;

sponsor-CRO indemnities;

cybersecurity breaches;

algorithmic clinical decisions;

genomic research;

biobank agreements;

termination of long-term research programmes.

31. Practical Legal Test

For a clinical research contract claim, use the following sequence:

1. Identify the contract
↓
2. Identify the parties
↓
3. Identify the governing law
↓
4. Identify the exact contractual obligation
↓
5. Check EU clinical-trial regulation
↓
6. Check mandatory national law
↓
7. Determine breach
↓
8. Determine causation
↓
9. Determine actual loss
↓
10. Examine indemnity/insurance
↓
11. Examine termination rights
↓
12. Determine appropriate remedy

32. Overall Conclusion

Clinical Research Contract Claims in Europe occupy a special position because they combine ordinary contract law with mandatory clinical-trial regulation, medical ethics, participant protection and national civil-liability rules.

The central contractual principle is that the CTA allocates commercial and operational responsibilities, but it cannot completely displace mandatory regulatory duties.

The most important EU rule is therefore the combination of Articles 71–76 of Regulation 536/2014:

Delegation is permitted, but delegation does not automatically eliminate sponsor responsibility; participant compensation must be available; and the substantive rules of civil liability, causation and damages remain largely governed by national law. (EUR-Lex)

The recent European case law is especially valuable because it shows that clinical-research litigation is not limited to participant injury. It can concern:

CTA performance — Citryll v QPS;

CRO liability and causation — DiaMedica v PRA;

clinical-trial data — DiaMedica v PRA;

institutional approval — Researchfonds v CWZ;

long-term research cooperation — Cardio Research v Reinier de Graaf;

participant safety and informed consent — Traskunova v Russia;

research funding and subcontracting — Verigraft v EISMEA.

Ultra-short revision formula

Clinical Research Contract → Sponsor/CRO/Hospital/Investigator → CTA → Protocol → Regulatory Duties → Performance → Data/IP → Safety → Breach → Causation → Damages/Specific Performance → Termination.